NICE u-turn approves first therapy for children with XLH

Final Recommendation We are absolutely thrilled to announce this morning that burosumab has been APPROVED for routine use on our NHS for children from 1 years up to young adults aged 16/17 years. This news completely changes the landscape for the estimated 250...

James Lind Alliance Rare Musculoskeletal Diseases PSP

Today we have launched the Rare Musculoskeletal Diseases in Adulthood Priority Setting Partnership (PSP). I’m very happy to share the outcomes from the James Lind Alliance Rare Musculoskeletal Diseases PSP. Many of you gave your time to submit questions and to...

Westminster Parliamentary Reception

[vc_row][vc_column][cs_headings style=”simple” title=”BBS Westminster Parliamentary Reception” text=”On Wednesday 6th June, XLH UK trustees were invited to attend a parliamentary reception at Westminster to celebrate the Brittle Bone...

ECTS 2018 report

XLH UK attended the European Calcified Tissue Society congress (ECTS) in Valencia, Spain. We were also fortunate to attend the first Rare Bone Group meeting alongside the congress to meet and work with other rare bone groups. Please do have a look at the report...